HIGHLIGHTS
- who: Ilona Hagelstein et al. from the Switzerland University of California, Davis have published the research: B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma, in the Journal: (JOURNAL)
- what: The authors report the preclinical characterization of an Fc-optimized B7-H3-targeting mAb termed 8H8_SDIE for treatment of sarcoma.
- how: Induction of target cell lysis by B7-H3targeting mAbs 8H8_SDIE and 8H8_WT Next the authors investigated whether the enhanced NK cell activity was mirrored in analyses of cytotoxicity. In previous studies the authors evaluated various mAbs and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.